105 related articles for article (PubMed ID: 15689166)
21. The desferrithiocin pharmacophore.
Bergeron RJ; Liu CZ; McManis JS; Xia MX; Algee SE; Wiegand J
J Med Chem; 1994 May; 37(10):1411-7. PubMed ID: 8182699
[TBL] [Abstract][Full Text] [Related]
22. Desferrithiocin analogue uranium decorporation agents.
Bergeron RJ; Wiegand J; Singh S
Int J Radiat Biol; 2009 Apr; 85(4):348-61. PubMed ID: 19399680
[TBL] [Abstract][Full Text] [Related]
23. Desferrithiocin: a search for clinically effective iron chelators.
Bergeron RJ; Wiegand J; McManis JS; Bharti N
J Med Chem; 2014 Nov; 57(22):9259-91. PubMed ID: 25207964
[TBL] [Abstract][Full Text] [Related]
24. The origin of the differences in (R)- and (S)-desmethyldesferrithiocin. Iron-clearing properties.
Bergeron RJ; Wiegand J; Ratliff-Thompson K; Weimar WR
Ann N Y Acad Sci; 1998 Jun; 850():202-16. PubMed ID: 9668541
[TBL] [Abstract][Full Text] [Related]
25. Development of tridentate iron chelators: from desferrithiocin to ICL670.
Nick H; Acklin P; Lattmann R; Buehlmayer P; Hauffe S; Schupp J; Alberti D
Curr Med Chem; 2003 Jun; 10(12):1065-76. PubMed ID: 12678677
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators.
Bergeron RJ; Wiegand J; Dionis JB; Egli-Karmakka M; Frei J; Huxley-Tencer A; Peter HH
J Med Chem; 1991 Jul; 34(7):2072-8. PubMed ID: 2066978
[TBL] [Abstract][Full Text] [Related]
27. Scaffold Based Search on the Desferithiocin Archetype.
Shyam M; Dev A; Sinha BN; Jayaprakash V
Mini Rev Med Chem; 2019; 19(19):1564-1576. PubMed ID: 30827237
[TBL] [Abstract][Full Text] [Related]
28. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.
Kicic A; Chua AC; Baker E
Anticancer Drug Des; 2001; 16(4-5):195-207. PubMed ID: 12049478
[TBL] [Abstract][Full Text] [Related]
29. Comparison of iron chelator efficacy in iron-overloaded beagle dogs and monkeys (Cebus apella).
Bergeron RJ; Wiegand J; Weimar WR; Lindstrom TC; Fannin TL; Ratliff-Thompson K
Comp Med; 2004 Dec; 54(6):664-72. PubMed ID: 15679265
[TBL] [Abstract][Full Text] [Related]
30. The design of orally active iron chelators.
Hider RC; Zhou T
Ann N Y Acad Sci; 2005; 1054():141-54. PubMed ID: 16339660
[TBL] [Abstract][Full Text] [Related]
31. A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.
Bergeron RJ; Streiff RR; Creary EA; Daniels RD; King W; Luchetta G; Wiegand J; Moerker T; Peter HH
Blood; 1993 Apr; 81(8):2166-73. PubMed ID: 8471775
[TBL] [Abstract][Full Text] [Related]
32. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
Dexter DT; Ward RJ; Florence A; Jenner P; Crichton RR
Biochem Pharmacol; 1999 Jul; 58(1):151-5. PubMed ID: 10403528
[TBL] [Abstract][Full Text] [Related]
33. Hydroxy(thio)pyrone and hydroxy(thio)pyridinone iron chelators: physico-chemical properties and anti-oxidant activity.
Chaves S; Canário S; Carrasco MP; Mira L; Santos MA
J Inorg Biochem; 2012 Sep; 114():38-46. PubMed ID: 22687564
[TBL] [Abstract][Full Text] [Related]
34. A non-human primate model for the study of oral iron chelators.
Wolfe LC; Nicolosi RJ; Renaud MM; Finger J; Hegsted M; Peter H; Nathan DG
Br J Haematol; 1989 Jul; 72(3):456-61. PubMed ID: 2765410
[TBL] [Abstract][Full Text] [Related]
35. Iron chelators for clinical use.
Tilbrook GS; Hider RC
Met Ions Biol Syst; 1998; 35():691-730. PubMed ID: 9444773
[No Abstract] [Full Text] [Related]
36. A comparative evaluation of iron clearance models.
Bergeron RJ; Streiff RR; Wiegand J; Vinson JR; Luchetta G; Evans KM; Peter H; Jenny HB
Ann N Y Acad Sci; 1990; 612():378-93. PubMed ID: 2127168
[TBL] [Abstract][Full Text] [Related]
37. Significance of asymmetric sites in choosing siderophores as deferration agents.
Bergeron RJ; Xin MG; Weimar WR; Smith RE; Wiegand J
J Med Chem; 2001 Jul; 44(15):2469-78. PubMed ID: 11448229
[TBL] [Abstract][Full Text] [Related]
38. Desferri-Exochelin, a lipid-soluble, hexadentate iron chelator, effectively removes tissue iron.
Hodges YK; Weinberger HD; Stephens J; Horwitz MA; Horwitz LD
Transl Res; 2006 Aug; 148(2):63-71. PubMed ID: 16890146
[TBL] [Abstract][Full Text] [Related]
39. Dual mechanism of mangiferin protection against iron-induced damage to 2-deoxyribose and ascorbate oxidation.
Pardo-Andreu GL; Delgado R; Núñez-Sellés AJ; Vercesi AE
Pharmacol Res; 2006 Mar; 53(3):253-60. PubMed ID: 16412661
[TBL] [Abstract][Full Text] [Related]
40. Protection against oxidative damage by iron chelators: effect of lipophilic analogues and prodrugs of N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine- N,N'-diacetic acid (OR10141).
Galey JB; Destrée O; Dumats J; Génard S; Tachon P
J Med Chem; 2000 Apr; 43(7):1418-21. PubMed ID: 10753479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
